Sobi’s avatrombopag study fails to meet primary endpointAnalysts, Business, Chemotherapy-Induced Thrombocytopenia, Clinical Trials, Primary Endpoints, R&D, Rivalries, Shares, Thrombopoietin (TPO) Receptor AgonistSwedish Orphan Biovitrum (Sobi) announced that the rare disease drug maker’s phase 3 study of avatrombopag did not meet the clinical trial’s primary endpoint, sending the company’s shares sharply down. Read more October 9, 2020/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2020-10-09 10:08:442020-10-09 12:36:11Sobi’s avatrombopag study fails to meet primary endpoint